Moreno, C., Greil, R., Demirkan, F., Tedeschi, A., Anz, B., Larratt, L., Simkovic, M., Samoilova, O., Novak, J., Ben-Yehuda, D., Strugov, V., Gill, D., Gribben, J. G., Hsu, E., Lih, C., Zhou, C., Clow, F., James, D. F., Styles, L., & Flinn, I. W. (2019). ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet oncology, 20(1), 43–56. http://access.bl.uk/ark:/81055/vdc_100076771279.0x00000c